Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Acute lymphoblastic leukemia (ALL)

Wolf-Hirschhorn syndrome candidate 1 (WHSC1; MMSET; NSD2)

Cell culture studies suggest inhibiting MMSET could help treat patients carrying activating mutations in the protein. In an analysis of the cancer cell line encyclopedia, an E1099K mutation in MMSET was identified in eight cell lines, seven of which were of lymphoid origin. The mutant MMSET cell lines displayed globally increased lysine H3K36 dimethylation compared with wild-type MMSET cell lines. Next steps include functional studies to test whether blocking MMSET activity could help treat cancers carrying the mutation.

SciBX 6(38); doi:10.1038/scibx.2013.1054
Published online Oct. 3, 2013

Unpatented; licensing status not applicable

Oyer, J.A. et al. Leukemia; published online July 26, 2013;
doi:10.1038/leu.2013.204
Contact: Relja Popovic, Northwestern University, Chicago, Ill.
e-mail:
r-popovic@northwestern.edu

Contact: Jonathan D. Licht, same affiliation as above
e-mail:
j-licht@northwestern.edu